Physicans' Financial News: October 2007

By Matthew Mahady
Published: Wednesday, Jun 30, 2010

Genentech Continues to Grow Oncology Portfolio

Over the past several years, South San Francisco–based Genentech has carved out a position as one of the clear industry leaders in the world of oncology biotech. Throughout 2007, the 31-year old company has continued to build on its past success, cultivating a richly diverse, highly promising developmental pipeline and capturing unprecedented marketshare with its currently approved stable of cancer therapy products.

Company Overview

Genentech’s achievements, of course, have not been limited to the oncology marketplace. Recently reported company highlights include FDA approval for Lucentis (ranibizumab injection), indicated for treatment of patients with neovascular age-related macular degeneration (a leading cause of blindness in people over the age of 55), seven product-line extensions (or new indications) since 2006 (including three in oncology), and major research breakthroughs that have fed a dramatically expanding product pipeline (Figure). Currently, the company boasts over 50 ongoing drug-development projects. In the second quarter of 2007 alone, Genentech announced the initiation of eight Phase III clinical trials.

Genentech’s line of currently approved oncology products includes Avastin (bevacizumab), which is indicated for use in combination with chemotherapy for first- or second-line treatment of patients with colon or rectum cancer and in combination with carboplatin and paclitaxel for the first-line treatment of patients with non-squamous non–small cell lung cancer; Herceptin (trastuzumab), utilized as first-line therapy in combination with paclitaxel, or as monotherapy in second- and third-line therapy for a number of breast cancer indications; Rituxan (rituximab), indicated as combination and monotherapy in a number of forms of non-Hodgkin’s lymphoma; and Tarceva (erlotinib), used for treating locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen and in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy.

Genentech Oncology Pipeline

    Drug Cancer Type
Phase I 14 Compounds Various types of cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0